Skip to content

Novo Nordisk Estonia OÜ

Registry code (registrikood) 16722379Private limited company (Osaühing)VAT EE102645279Activity (EMTAK 46461): Ravimite ja muude apteegikaupade hulgimüükActive

Tallinn, Harju County · Financial data: annual reports up to 2025; tax data up to 2026 Q3

Revenue (2025)
€37.0M
▲ 31.1% vs 2024
Profit before tax (2025)
€1.4M
Employees, FTE (2025)
21
State taxes paid, last 4 quarters
€4.8M

Revenue, profit and employees, 2023–2025

€6.0M2023€28.2M2024€37.0M2025
YearRevenue (müügitulu)Operating profit (ärikasum)Net profitEquity (omakapital)Employees, FTE
2023€6,027,246€210,891€217,418€417,41816
2024€28,225,863€985,980€1,012,767€1,430,18518
2025€37,002,060€1,286,474€1,366,700€2,796,88521

Balance sheet summary

YearCashTotal assetsCurrent liabilitiesNon-current liabilitiesEquity
2023€294,710€5,191,016€4,728,826€44,772€417,418
2024€141,825€7,411,786€5,932,219€49,382€1,430,185
2025€145,606€12,117,439€9,253,790€66,764€2,796,885

Calculated ratios

Net profit margin = net profit ÷ revenue. Equity ratio = equity ÷ total assets. Seedata sources & methodology for how each figure is derived.

Quarterly tax and turnover data (EMTA)

QuarterState taxes paidWage taxesTurnoverEmployees
2022 Q1———13
2022 Q2———13
2022 Q3———14
2022 Q4———16
2023 Q1———16
2023 Q2———16
2023 Q3———16
2023 Q4€366,887€88,337€6,306,33016
2024 Q1€696,754€136,630€10,614,13325
2024 Q2€745,084€255,330€10,954,38718
2024 Q3€836,003€188,000€13,123,73119
2024 Q4€984,880€200,812€15,906,13018
2025 Q1€833,827€188,049€14,633,97021
2025 Q2€940,748€355,708€12,969,70521
2025 Q3€1,144,112€239,728€17,624,57022
2025 Q4€999,503€240,876€17,529,95722
2026 Q1€1,208,597€220,660€25,399,02920
2026 Q2€1,305,190€320,376€19,169,60220
2026 Q3€1,274,856€234,504€27,063,02719

Source: EMTA quarterly published data, as of 10 October 2026. Covers state taxes and wage taxes actually paid and turnover and employee counts as declared by the company, not the annual report figures above.

About this data

In the 2025 financial year (period 1 January 2025–31 December 2025), Novo Nordisk Estonia OÜ reported revenue of €37,002,060.

The company closed the 2025 financial year with a net profit of €1,366,700.

Revenue increased by 31.1% from €28,225,863 in 2024 to €37,002,060 in 2025.

Revenue grew at a compound annual rate of 147.8% between 2023 and 2025.

Equity accounted for 23.1% of total assets of €12,117,439 at the end of the 2025 reporting period.

With 21 full-time-equivalent employees in 2025, revenue per employee was €1,762,003.

Across the 4 most recent quarters declared to EMTA, up to Q3 2026, Novo Nordisk Estonia OÜ reported €89,161,615 in turnover.

EMTA recorded 19 employees for the quarter ending Q3 2026, compared with 21 full-time-equivalent employees in the 2025 annual report.

Browse

Source

Source: Estonian e-Business Register open data (Centre of Registers and Information Systems, RIK), licence CC BY-SA 4.0, modified; Estonian Tax and Customs Board (EMTA) quarterly data. Downloaded 2026-11-16. This is not an official register extract — see ariregister.rik.ee.

Company data on this site is available under CC BY-SA 4.0.

To request a correction or the removal of this page, use the contact form. Removal requests are handled within 30 days, no justification required.